Skip to content

Precigen PGEN Papzimeos — Total revenues

Other product segments

Exemplar
$1.33M

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYZeposia — Total Revenues
$118M+10.3%
Incyte logo
INCYPEMAZYRE — Total revenues
$22.54M+22.3%
BioMarin Pharmaceuticals logo
BMRNPALYNZIQ — Total revenues
$89.56M-4.0%
Amgen logo
AMGNTEPEZZA — Total revenues
$490M+28.6%
Incyte logo
INCYOPZELURA — Total revenues
$143.02M+20.5%
Amgen logo
AMGNTEZSPIRE — Total revenues
$343M+20.4%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's papzimeos — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's papzimeos — total revenues?
Precigen (PGEN) reported papzimeos — total revenues of $21.59M in Q1 2026.
What does papzimeos — total revenues mean?
This metric represents the total gross revenue generated by the Papzimeos product line or service segment from transactions with external customers. It serves as a key indicator of the commercial adoption and market penetration of this specific biotechnology offering within the company's broader synthetic biology portfolio. Tracking this revenue stream helps investors assess the segment's ability to transition from development phases to meaningful market contribution.